Vivodyne is rendering inaccurate animal testing obsolete, using automated robotic platforms and AI to grow and analyze thousands of fully functional human tissues. Pharmaceutical companies historically have spent millions on clinical trials destined to fail 95% of the time because animal models are poor predictors of human biology. Vivodyne solves this problem by providing unprecedented, clinically relevant human data at massive scale. Already used by most top pharma companies, Vivodyne's platform significantly reduces trial risk, accelerates drug discovery, and brings safer, more effective therapies to patients faster.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/29/25	$40,000,000	Series A	Bison Ventures CS Ventures Fortius Ventures Helena Capital Kairos Ventures Khosla Ventures Lingotto Investment Management MBX Capital	undisclosed